Tag: MHRA

MHRA: No Summer Shortcut for Safe Weight Loss

Healthy weight loss takes time, not shortcuts. As demand for weight-loss medicines continues to rise, the MHRA is reminding people how to use GLP-1 medicines safely, spot illegal sellers and avoid diet changes that could interfere with their medicines

With prescription weight loss medicines being advertised illegally on social media alongside quick-fix slimming claims, the Medicines and Healthcare products Regulatory Agency (MHRA), warns Brits to not let summer slimming put their health at risk. 

From over-dosing on prescription weight-loss meds to buying dangerous fakes online, the MHRA reveals the mistakes that could leave you seriously ill, and the simple steps to lose weight safely. 

1. Follow doctor’s orders if you are prescribed a GLP-1 

If you’ve been prescribed a GLP-1 weight-loss medicine, don’t be tempted to fast-track your weight loss by upping your dose. Semaglutide (Wegovy), tirzepatide (Mounjaro) and liraglutide (Saxenda) should only be taken as prescribed by a healthcare professional.  

Follow doctors’ orders and take your prescribed GLP-1 alongside a healthy diet and a fitness regime. Whether you’re taking it for diabetes management or weight loss, maintaining good nutrition and exercise can help support muscle, bone, and overall health as your calorie intake changes. 

2. Steer Clear of Fake Weight-Loss Meds 

If you’re not eligible for a prescription for weight-loss medicines, don’t be tempted to buy them from unregulated websites or social media sellers. GLP-1 medicines authorised in the UK have only been shown to be safe and effective for people with a Body Mass Index (BMI) of 27 or more. Buying from rogue sellers is a huge risk. You can’t be sure what’s in the product, and some fake medicines are contaminated with toxic substances. 

Don’t be tempted by the online hype around retatrutide. It has not been authorised for use in the UK, meaning anyone selling this product is doing so illegally. These products haven’t been tested for safety, quality or effectiveness and there’s no guarantee that they even contain retatrutide. You could be putting your health at serious risk. 

Head of the MHRA’s Criminal Enforcement Unit, Andy Morling, said: “Rogue sellers are driven by profit, not your safety, and the fake medicines they sell could put your health at serious risk.

“These products may not contain the GLP-1 medicine you think you’re buying and could be contaminated with bacteria and other harmful substances.  

“Be wary of deals that seem too good to be true and check the pharmacy is registered with the General Pharmaceutical Council. The simple rule for staying safe is that if you’re offered a GLP-1 medicines without the need for a prescription – walk away.” 

3. Check Your Meds Before Changing Your Diet 

Trying to eat more healthily before your holiday? Great – but make sure your diet doesn’t clash with your medication. Always read the patient information leaflet before making dietary changes, as some foods could compromise medicines’ effectiveness. People taking simvastatin to lower their cholesterol should avoid grapefruit and grapefruit juice as they slow the rate the body breaks down the medicine, increasing the risk of serious side effects. 

Thinking about intermittent fasting? Remember that some medicines need to be taken with food to work most effectively and lower your risk of side effects. Metformin, used to treat diabetes, and the painkiller naproxen should both be taken with or after food to help prevent stomach upset.  

MHRA’s Chief Safety Officer, Alison Cave said: “There’s no shortcut to safe weight loss. If you’re trying to slim down, follow medical advice, avoid fake medicines and remember that healthy eating and regular exercise are still the safest ways to get in shape for summer.” 

Counterfeit Weight-Loss Pills Could Be the Next Online Health Scam

Pharmacist reveals the warning signs that a weight-loss medicine may be fake as the first GLP-1 tablet is approved in the UK

Consumers are being warned to watch for fake weight-loss tablets appearing on social media and unregulated websites following the approval of the first oral GLP-1 medicine for weight management in the UK.

The Medicines and Healthcare products Regulatory Agency approved the semaglutide tablet for weight loss on 11 June 2026, creating a needle-free alternative to injectable treatments.

However, Sobia Qasim, Superintendent Pharmacist at Curely, warns that growing public interest in weight-loss pills could also create a new opportunity for illegal sellers.

Unlike injectable pens, tablets can be placed in ordinary bottles, blister packs or envelopes and posted without specialist equipment, potentially making counterfeit products appear more convincing to consumers.

Fake medicines may contain the wrong dose, no active ingredient or entirely different and potentially harmful substances. The MHRA has already uncovered organised criminal networks manufacturing illegal weight-loss medicines and seized almost £45 million worth of illegal medicines during 2025.

Sobia said: “The arrival of an approved weight-loss tablet is an important development for patients, particularly those who are uncomfortable with injections. However, high demand and widespread online interest can also attract illegal sellers looking to exploit people who want quick or cheaper access.

“A tablet may look less suspicious than an injection because consumers are accustomed to receiving pills through the post. But a professional-looking box, blister pack or website does not prove that the medicine is genuine.

“Prescription weight-loss medication should only be supplied after an appropriate clinical assessment by a qualified healthcare professional. Any seller willing to bypass that process should immediately raise concern.”

Seven signs a weight-loss pill could be fake

Warning signWhy it should raise concern
It is sold through social media messagesGenuine prescription medicines should not be bought through private messages, marketplace listings or informal social media accounts.
No medical consultation is requiredWeight-loss medication is not suitable for everyone. A regulated provider should assess your health, current medicines and eligibility before prescribing it.
The seller guarantees a specific amount of weight lossResults differ between patients. Guaranteed outcomes are a marketing tactic, not responsible clinical advice.
You are pressured to act quicklyCountdown timers, limited stock claims and urgent payment requests may be used to stop consumers checking whether a provider is legitimate.
The price appears unusually lowA price substantially below recognised providers may indicate that the medicine is fake, unlicensed, incorrectly stored or obtained illegally.
The tablets arrive loose or in unfamiliar packagingMedicines should arrive in sealed, labelled packaging with clear dosage information and a patient information leaflet.
There is no registered pharmacy informationConsumers should be able to identify the pharmacy supplying the medicine and verify that it is registered with the appropriate UK regulator.

A familiar brand name does not guarantee a genuine product

Sobia warns that counterfeiters may copy recognised brand names, logos, batch numbers and packaging to make illegal products appear authentic.

In February 2026, the MHRA confirmed that a falsified version of a Mounjaro injection had been supplied through an online pharmacy in the UK. The regulator said fake medicines may contain incorrect ingredients, no active ingredient or harmful substances.

Previous fake GLP-1 injections discovered in the UK have also contained insulin, creating a risk of dangerously low blood sugar for people who unknowingly used them.

Sobia continued: “Counterfeiters can reproduce colours, logos and packaging extremely convincingly. Consumers should never judge a medicine by appearance alone.

The checks around the medicine are just as important as the product itself. Who prescribed it? Was a proper consultation completed? Which registered pharmacy supplied it? Can you contact a healthcare professional if something goes wrong?

“If those questions cannot be answered clearly, do not take the tablets.”

What consumers should check before ordering

Before purchasing weight-loss medication online, Curely recommends checking that:

  • Genuine clinical assessment is required
  • Qualified prescriber reviews the order
  • The dispensing pharmacy is registered in the UK
  • The provider asks about existing health conditions and medication
  • Clear contact details are available
  • The medicine arrives sealed and properly labelled
  • Instructions and patient safety information are included
  • Follow-up support is available throughout treatment

The NHS warns that medicines bought from unregistered websites may be out of date, diluted, fake or unsuitable for the person taking them.

What to do if you think a weight-loss medicine is fake

Anyone who believes they have received a counterfeit or suspicious medicine should not take another dose until they have spoken to a pharmacist or doctor.

Consumers should keep the packaging, receipt and details of the website or seller. Suspected fake medicines and side effects can be reported through the MHRA Yellow Card scheme.

Those who experience severe or persistent abdominal pain, repeated vomiting, difficulty breathing, loss of consciousness or symptoms of dangerously low blood sugar should seek urgent medical assistance.

Sobia added: “People may feel embarrassed if they have bought medication from an unofficial seller, but healthcare professionals need to know exactly what may have been taken so they can provide the right treatment.

Do not throw the packaging away and do not assume that feeling unwell is simply a normal side effect. With an unregulated product, there is no reliable way to know what the tablet contains or what dose has been supplied.

The safest route is always a properly regulated service offering clinical assessment, genuine medication and ongoing professional support.”

https://www.curely.co.uk/ 

Two arrested during the MHRA’s largest ever seizure of unlicensed weight loss medicines

Officers from the Medicines and Healthcare products Regulatory Agency’s (MHRA) Criminal Enforcement Unit have arrested two people after raiding a country estate near Northampton, recovering around 12,000 doses of unlicensed weight loss medicines in the largest ever seizure of such products by the agency.

During the operation, which was carried out last night (28 May 2026) with the support of Northamptonshire Police, two male suspects, both aged 29, were arrested on suspicion of offences under the Human Medicines Regulations 2012.  Enquiries are ongoing.  

The property is believed to have been used as a large-scale facility to manufacture, assemble, and distribute unlicensed weight loss medicines, including retatrutide and tirzepatide, as well as peptide products. 

Officers seized substantial quantities of packaging materials and what are believed to be pharmaceutical substances used in the illicit manufacture of the products. 

Andy Morling, Head of the MHRA’s Criminal Enforcement Unit, said: “Last night’s hugely successful operation demonstrates, once again, the MHRA’s unwavering commitment to ensuring there is no hiding place for those who cynically put the public’s health at risk for profit. Medicines regulation isn’t discretionary – it exists to protect people.   

“That’s why we continue to target the traffickers who seek to bypass that protection – taking down the infrastructure that supports them and creating a hostile environment for their exploitative and harmful trade. In addition to disrupting an organised criminal group, I’m confident that dismantling this illicit production facility will have prevented significant public harm.

“I’m enormously grateful to Northamptonshire Police for their support in this operation.”

This operation is the latest in a series of successful enforcement actions by the MHRA targeting the illegal supply of weight loss medicines. Over recent months, the agency’s Criminal Enforcement Unit has carried out several raids, dismantling criminal networks, and removing significant quantities of unlicensed and potentially dangerous products from circulation.  

The MHRA remains committed to pursuing those who seek to exploit public demand for these medicines and will continue to use the full range of its powers to protect the public. 

The MHRA #FakeMeds website offers helpful guidance and advice for staying safe when buying medicines online.   

Anyone who suspects they are having a side effect from a medicine are encouraged to talk to their doctor, pharmacist or nurse and report it directly to the MHRA Yellow Card scheme. 

Seven sentenced after MHRA investigation uncovers £1.8m illegal medicines and steroids network

An MHRA-led investigation has exposed a £1.8 million illegal medicines and steroids network, leading to seven men being sentenced

Seven men have been sentenced after an investigation by the Medicines and Healthcare products Regulatory Agency’s (MHRA) Criminal Enforcement Unit into a large-scale criminal network supplying illegal steroids and prescription-only medicines. The group received combined sentences totalling more than 21 years’ imprisonment. 

The investigation began after UK Anti-Doping (UKAD) identified website linked to the Bolton area that were suspected of selling performance-enhancing steroids and other illegal medicines. 

MHRA investigators traced the activity to a flat above commercial premises on St Helens Road, which was being used to store, package, and distribute the drugs. 

During enforcement action, officers seized more than 130,000 doses of steroids and unauthorised medicines that were being sold by mail order. These included products such as tamoxifen, finasteride and modafinil, highlighting the scale and complexity of the illegal supply network. Further searches across Bolton led to a number of arrests. 

Following a detailed investigation, several individuals were charged with offences including conspiracy to supply controlled drugs, supplying unauthorised medicines, and money laundering to the value of over £1.8 million.  

Tim Duffield, MHRA Head of Intelligence said: ““This was a well-organised operation that put people at real risk. Medicines bought outside regulated channels can be unsafe, ineffective or fake. 

“Our investigators worked hard to break up this criminal network and bring those responsible to justice. These convictions are just part of the MHRA’s ongoing work to tackle the illegal trade in medicines and protect public health.” 

Mario Theophanous, UKAD’s Head of Intelligence and Investigations, said: “Disrupting the supply of illegal performance-enhancing drugs is central to protecting sport.

“Our intelligence officers work in partnership with regulators and law enforcement, to identify and dismantle the criminal networks that make these substances available. That collaboration is a vital part of how we keep prohibited substances out of sport, and away from elite athletes and young people.” 

Zaheer Oomer, who is unemployed, pleaded guilty at an early stage to all charges, including money laundering offences to a value of £99,893.  

Rizwan Atcha, a health and safety advisor, Imtiaz Atcha, a former bank manager, and Matthew Williams, a care worker, also pleaded guilty at the start of the trial in June 2025. Each admitted money laundering offences to the value of £772,112, £117,733 and £221,349 respectively.

Abdul Khan, a scrap metal dealer, Saddym Shahid, a mechanic, and Rajendra Patel, a scrap metal worker, pleaded not guilty and stood trial at Bolton Crown Court. They faced charges of money laundering involving £139,967, $248,750 and £229,061 respectively. Following consideration of extensive evidence, the jury found all three men guilty on 7 July 2025. 

A Proceeds of Crime Act confiscation investigation is ongoing. 

The MHRA reminds the public to only obtain medicines from trusted and regulated sources, such as registered pharmacies.

Anyone who suspects they have been sold illegal or unsafe medicines, or is experiencing side effects, should seek medical advice and report any concerns to the MHRA’s Yellow Card scheme.  

Convictions 

  • Abdul Khan and Saddaym Shahid – Conspiracy to supply class C drugs 4 years imprisonment. Conspiracy to supply unauthorised medicinal products 18 months imprisonment concurrent. Money laundering 3 years imprisonment consecutive. Total 7 years imprisonment. 
  • Mohammed Oomer – Conspiracy to supply class C drugs 35 months imprisonment. Conspiracy to supply unauthorised medicinal products 18 months imprisonment concurrent. Money laundering 20 months imprisonment consecutive. Total 4 years 7 months. 
  • Rizwan Atcha – 4 counts of money laundering. 37 months imprisonment concurrent on each count. Total 3 years and 1 month imprisonment. 
  • Imtiaz Atcha – 4 counts of money laundering. 18 months imprisonment suspended for 2 years. Electronically monitored curfew from 9pm to 7pm for four months. To do 250 hours of unpaid work.  
  • Rajendra Patel – 2 counts of money laundering. 24 months imprisonment suspended for 2 years. Electronically monitored curfew from 9pm to 7pm for four months. To do 250 hours of unpaid work. 
  • Matthew Williams – 4 counts of money laundering. 24 months imprisonment suspended for 2 years. Electronically monitored curfew from 9pm to 7pm for four months. To do 250 hours of unpaid work. 

20 million illegal erectile dysfunction pills seized as MHRA warns against risky online buys

People are urged to avoid risky online buys and protect their health, as the MHRA seizes over 4.4 million doses of unlicensed erectile dysfunction medicines in 2025 alone

Nearly 20 million illegally traded erectile dysfunction pills have been seized in just five years – equivalent to a single dose for three in every four adult men in the UK – as the Medicines and Healthcare products Regulatory Agency (MHRA) warns people not to risk their health by buying unauthorised medicines online. 

Between 2021 and 2025, the MHRA’s Criminal Enforcement Unit seized around 19.5 million doses of erectile dysfunction medicines, including 4.4 million in 2025 alone, working closely with Border Force to intercept shipments and disrupt organised criminal networks.  

Many of the pills seized, enough to fill two double-decker buses, were illegally sold online and contained no active ingredient, the wrong dose, hidden drugs or toxic ingredients.  

Erectile dysfunction medicines remain one of the most frequently seized illegally traded medicines in the UK, with yearly seizures more than doubling since 2022. 

Dr Zubir Ahmed, Health Innovation and Safety Minister, said: “There should be no shame in talking about erectile dysfunction, but stigma and embarrassment are being exploited by criminals selling fake medicines that can be deadly.  

“We’re cracking down on crime and as a doctor, my message is simple: speak to your GP or pharmacist. They can offer safe, effective treatments and confidential advice, taking into account your health and any other medicines you take. 

“Don’t take a gamble with your health. If a medicine isn’t coming from a registered pharmacy, it isn’t safe – and it’s breaking the law.”

Andy Morling, Head of the MHRA’s Criminal Enforcement Unit, said: “These seizures show the sheer scale of the illegal market for erectile dysfunction medicines in the UK – and the risks people are taking without realising. 

“Any medicine not authorised for sale in the UK can be unsafe or ineffective and there is no way of knowing what is in them or the negative health effects they can have. These pills may look genuine, but many are potentially dangerous. These products may contain no active ingredient, the wrong dose, hidden drugs or toxic ingredients. 

“I’m incredibly pleased we’ve taken almost 20 million doses of unauthorised erectile dysfunction medicines off the streets, including 4.4 million last year alone, in what was a record-breaking year of total seizures for the MHRA. Each and every one of those products was potentially dangerous to the public.”

Alongside major seizures, the MHRA’s Criminal Enforcement Unit is stepping up action against online sellers. Working with internet service providers, they disrupted more than 1,500 websites and social media accounts illegally selling medical products to the public in 2025 and removed more than 1,200 social media posts during the year. 

Health risks of unauthorised medicines 

Despite erectile dysfunction being common, affecting around half of men aged 40 to 70, research suggests two in five men would avoid seeking medical advice, pushing some towards unsafe online sellers. 

The MHRA is warning people: if you buy erectile dysfunction medicines from unregulated websites, social media or messaging apps, you are gambling with your health. 

Unlicensed erectile dysfunction medicines can be especially dangerous for people with heart disease, high blood pressure, or those taking other medications, and can raise the risk of heart attack, stroke and dangerously low blood pressure. 

Public advice 

The MHRA urges people to: 

  • Avoid buying medicines from social media, messaging apps or unknown websites. Visit the #FakeMeds website for tools and resources to help you obtain medicines and medical devices safely online. 
  • Only use UK-registered pharmacies, including online pharmacies displaying the official green cross logo. For online pharmacies based in Great Britain you can check on the General Pharmaceutical Council’s (GPhC) website that it is properly registered. 
  • Speak to a GP or pharmacist about safe and effective treatment options. 

Anyone concerned about suspicious medicines or websites can report them through the MHRA’s Yellow Card scheme. 

MHRA statement on new review of paracetamol safety during pregnancy

Paracetamol should be taken as directed in the patient information leaflet

Following publication of a new systematic review and meta-analysis in The Lancet Obstetrics, Gynaecology, & Women’s Health which found no evidence that paracetamol use during pregnancy increases the risk of autism spectrum disorder, ADHD or intellectual disability among children, the MHRA has reaffirmed that paracetamol continues to be the safest option for managing pain and fever during pregnancy.

Dr Alison Cave, Chief Safety Officer at the MHRA, said: “Paracetamol remains safe to use during pregnancy. This large-scale analysis of the evidence found no link between taking paracetamol during pregnancy and autism, ADHD, or disability in children.

“Paracetamol has been used for many years and is the recommended first choice for treating pain or fever during pregnancy. When taken as directed, it is safe and effective.

“As with all medicines, pregnant women should speak to their doctor, pharmacist or midwife if they have any questions, and follow the guidance provided with the medicine.”

Paracetamol is recommended as the first-choice painkiller for pregnant women, used at the lowest dose and for the shortest duration.

If pain does not resolve, then patients are advised to seek advice from their healthcare professional.

See NHS Guidance – Pregnancy, breastfeeding and fertility while taking paracetamol for adults 

MHRA approves zapomeran (Kostaive) mRNA COVID-19 vaccine

The Medicines and Healthcare products Regulatory Agency (MHRA) yesterday (2 January 2026) approved zapomeran (Kostaive) mRNA COVID-19 vaccine, for the immunisation of individuals aged 18 years of age and older. 

Zapomeran is given as a single 0.5 mL booster dose by injection into the muscle of the upper arm. It contains a self-amplifying messenger RNA (sa-mRNA) which instructs the body’s cells to temporarily make the SARS-CoV-2 spike protein.

This teaches the immune system to fight off the virus in the future.  

Julian Beach, Interim Executive Director of Healthcare Quality and Access at the MHRA, said: “Patient safety is our top priority. 

“The approval of zapomeran (Kostaive) provides an alternative vaccine for use in adults to prevent COVID-19 caused by SARS-CoV-2.  

“As with all licensed medicines, we will continue to monitor its safety closely as it becomes more widely used.”

Very common side effects (which may affect more than 1 in 10 people) include pain or tenderness at the injection site, tiredness, chills, fever, muscle and joint pain, headache and dizziness. Most side effects are mild and disappear within a few days of vaccination.  

A full list of side effects can be found in the Patient Information Leaflet (PIL) or the Summary of Product Characteristics (SmPC), which will be published on the MHRA website within 7 days of approval. 

As with any medicine, the MHRA will keep the safety and effectiveness of zapomeran under close review.

Anyone who suspects they are having a side effect from this medicine is encouraged to talk to their doctor, pharmacist or nurse and report it directly to the MHRA Yellow Card scheme, either through the website (https://yellowcard.mhra.gov.uk) or by searching the Google Play or Apple App stores for MHRA Yellow Card. 

MHRA calls on public to report side effects and suspected fakes during #MedSafetyWeek

The tenth annual #MedSafetyWeek brings together more than 130 medicines regulators and health organisations across 117 countries to encourage people to report suspected side effects from medicines and device incidents

The Medicines and Healthcare products Regulatory Agency (MHRA) is urging the public to help keep medicines, medical devices, vaccines and blood products safe by reporting any side effects, device incidents and suspected fake medical products, as part of #MedSafetyWeek (3–9 November).  

The global campaign is marking its tenth year, bringing together more than 130 regulators and health organisations across 117 countries with one shared message: everyone has a role to play in medicine safety. 

Reporting matters more than ever 

With more people using medicines and medical devices than ever before – from weight loss treatments to wearable monitors – safety reporting is a key part of protecting public health.  

An estimated 2.5 million people in the UK are now using weight loss medicines, many bought online and delivered by post. Thousands use glucose sensors or blood-pressure monitors in the comfort of their own homes.

As medicines and medical devices play a bigger role in daily life, including to prevent illness rather than treat it, public reporting of safety concerns is more important than ever. 

Professor Anthony Harnden, MHRA Chair, said: “Healthcare has changed significantly over the past decade, alongside advances in science and technology. Medicines and medical devices are part of everyday life for millions of people, and many are accessed in new ways, including online.  

“If you experience a side effect, notice a device isn’t working properly, or suspect a fake medical product, please tell us via the MHRA’s Yellow Card scheme. Your report could protect others – and it only takes minutes.” 

Real-world reports, real-world impact  

Reports to the MHRA’s Yellow Card scheme – the UK’s system for flagging concerns about medicines and medical devices – help keep the public safe.  

In the past year, reports have: 

Reports also support our criminal investigations into fake or unlicensed medicines; or research such as the Yellow Card Biobank study in collaboration with Genomics England, exploring why people respond to medicines differently, helping pave the way for more personalised treatments.  

Alison Cave, Chief Safety Officer at the MHRA, said: “Every Yellow Card report matters because it adds to our understanding of how medicines, medical devices and vaccines perform in the real world.

“Clinical trials involve thousands of people, but once a product is used by millions, patterns emerge that we couldn’t see before. Your report might be the one that helps us connect the dots and protect others. Importantly you don’t need to be certain about the cause – just tell us what you’ve experienced.” 

We all have a role to play – how to report 

Since its launch in 1963, the Yellow Card scheme has collected more than 1.3 million reports, with the public now its largest contributors.  

To help build awareness from an early age, information about the Yellow Card scheme has now been introduced into England’s school curriculum, teaching children why reporting helps protect others.  

Anyone – patients, carers, pharmacists, nurses, doctors – can report through the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk. 

Please report: 

  • Side effects – even if you’re unsure they’re linked to your medicine.  
  • Medical device problems – such as faults or unexpected behaviour. 
  • Suspected fake products – especially those bought online or via social media.  

The MHRA’s FakeMeds campaign provides advice to people in the UK who are considering buying medication online, outlining how products can be accessed from safe and legitimate sources.  

Throughout #MedSafetyWeek, the MHRA will share safety messages on social media to encourage people to tell them about medicine and medical device concerns.  

MHRA smashes major illicit weight loss medicine production facility in record seizure

MHRA strikes massive blow to organised criminal gang in world’s biggest illegal weight loss jabs raid

Officers from the Criminal Enforcement Unit (CEU) of the Medicines and Healthcare products Regulatory Agency (MHRA) have dismantled a major illicit manufacturing facility, making and distributing unlicensed weight-loss jabs, during a raid on a warehouse in Northampton.  

This is the first illicit production facility for weight loss medicine discovered in the UK and is believed to be the largest single seizure of trafficked weight loss medicines ever recorded by a law enforcement agency worldwide.  

During the search, MHRA officers, supported by Northamptonshire Police, seized tens of thousands of empty weight loss pens ready to be filled, raw chemical ingredients, and more than 2,000 unlicensed retatrutide and tirzepatide pens awaiting dispatch to customers. The street value of the finished weight loss products alone is estimated to be more than a quarter of a million pounds. 

Along with large amounts of sophisticated packaging and manufacturing equipment, officers recovered approximately £20,000 in cash suspected to be linked to medicines trafficking. 

The search operation, lasting two days, is the latest in the MHRA’s ongoing work to tackle the illegal trade in weight loss medicines.

The site, on an industrial estate on the outskirts of Northampton, is believed to have been used for the large-scale manufacture, packaging, and distribution of unlicensed — and potentially deadly — weight loss products to customers.  

Secretary of State for Health and Social Care, Wes Streeting, said: “This is a victory in the fight against the shameless criminals who are putting lives at risk by peddling dangerous and illegal weight loss jabs to make a quick buck. 

“These unregulated products, made with no regard for safety or quality, posed a major risk to unwitting customers. 

“My message is clear: don’t buy weight loss medications from unregulated sources. Talk to your GP, seek NHS advice, and don’t line the pockets of criminals who don’t care about your health.

“Safe, appropriate, licensed obesity drugs can greatly benefit those in need if taken under medical supervision, and I urge people to only purchase and use them with the approval and oversight of medics and pharmacists.” 

Andy Morling, Head of the MHRA’s Criminal Enforcement Unit, said:  “This seizure shows the lengths these criminals will go to for profit. People should be extremely cautious when buying medicines online.

“Prescription medicines should only be obtained from a registered pharmacy against a prescription issued by a healthcare professional.

“Taking prescription medicines sourced in any other way carries serious risks to your health – there are no guarantees about what they contain, and some may even be contaminated with toxic substances. 

“Taking out the first illicit weight loss medicine manufacturing facility found in the UK is a landmark result for the MHRA and a major blow to the illegal trade. These products are untested, unauthorised, and potentially deadly. By taking this organised criminal network out of operation and stopping tens of thousands of potentially fatal products from entering circulation, we’ve prevented a serious risk to public health. 

“This is an illicit global market that endangers patients, puts big money in the pockets of organised criminals, and undermines legitimate healthcare. This operation demonstrates, once again, that my officers will stop at nothing to identify, disrupt, and dismantle the organised criminal networks who put profit before safety.”  

The MHRA #FakeMeds website offers helpful guidance and advice for staying safe when buying medicines online.  

Anyone who suspects they are having a side effect from a medicine are encouraged to talk to their doctor, pharmacist or nurse and report it directly to the MHRA Yellow Card scheme. 

MHRA: NO EVIDENCE that taking paracetamol during pregnancy causes autism in children

There is no evidence that taking #paracetamol during pregnancy causes autism in children.

Always follow NHS guidance and report any suspected side effects via the Yellow Card scheme https://bit.ly/2A6B165

Dr Alison Cave, Chief Safety Officer at the MHRA, said: “Patient safety is our top priority. There is no evidence that taking paracetamol during pregnancy causes autism in children.   

“Paracetamol remains the recommended pain relief option for pregnant women when used as directed. Pregnant women should continue to follow existing NHS guidance and speak to their healthcare professional if they have questions about any medication during pregnancy.

“Untreated pain and fever can pose risks to the unborn baby, so it is important to manage these symptoms with the recommended treatment. 

https://twitter.com/i/status/1970506529125064995

“Our advice on medicines in pregnancy is based on rigorous assessment of the best available scientific evidence. 

“Any new evidence that could affect our recommendations would be carefully evaluated by our independent scientific experts. 

“We continuously monitor the safety of all medicines, including those used during pregnancy, through robust monitoring and surveillance. We encourage anyone to report any suspected side effects to us via the Yellow Card scheme.”

Paracetamol is recommended as the first-choice painkiller for pregnant women, used at the lowest dose and for the shortest duration.

If pain does not resolve, then patients are advised to seek advice from their healthcare professional.

See NHS Guidance – Pregnancy, breastfeeding and fertility while taking paracetamol for adults 

Scottish Autism is aware that pronouncements regarding autism from the US Government will be a source of anxiety and worry for many in our community.

We are clear that public policy should be focused on recognising and accommodating the needs and rights of autistic people rather than stigmatising neurodivergence as something to be ‘treated’ or prevented. Spreading misinformation about the identified reasons why some people are born autistic does nothing to further this aim.

Scottish Autism’s focus is on finding better ways to support autistic people and their families. Our research, campaigning and service provision reflect this priority and always will.

Our Advice Line is open 10am-4pm Monday, Tuesday, Thursday & Friday and our Community Advisors can help you to identify what support may exist in your area.

You can call the Advice Line on 01259 222022, email advice@scottishautism.org or LiveChat with us via our website.

MHRA crackdown on illegal ‘Botox’ after victims left seriously ill

More than 40 people hospitalised following suspected use of unlicensed botulinum toxin products

The Medicines and Healthcare products Regulatory Agency (MHRA) is warning criminals that they face prison as it cracks down on the illicit trade in unlicensed botulinum toxin products, commonly referred to as Botox, used in cosmetic procedures. 

The MHRA’s Criminal Enforcement Unit has launched a number of criminal investigations following a spike in hospital admissions believed to be linked to the use of unlicensed botulinum toxin products.

Between 4 June and 6 August 2025, 41 confirmed cases of botulism – a rare but potentially life-threatening condition causing paralysis – were reported across several regions in England, including the North East, East Midlands, East of England, North West, and Yorkshire and Humber. 

The Criminal Enforcement Unit has seen evidence that some sellers and practitioners – often untrained – are obtaining unlicensed botulinum toxin products illegally and offering injections in unsafe, unregulated settings.

The treatments are being delivered in informal settings such as domestic bedrooms and kitchens, hair salons, and through mobile beauty services. Members of the public are often lured in by adverts on social media promising quick, cheap results. 

The Criminal Enforcement Unit is investigating the illegal trade in these products. Anyone caught selling or supplying unlicensed botulinum toxin faces up to two years in prison and unlimited fines under the Human Medicines Regulations 2012. 

Andy Morling, Head of the MHRA’s Criminal Enforcement Unit, said: “Criminals are exploiting the popularity of cosmetic treatments by peddling dangerous, unlicensed products, putting profit before safety.

“Anyone involved in the supply of unlicensed botulinum toxin – whether through organised networks or informal sales from kitchen tables, hair salons, or via social media – is breaking the law and endangering lives. The 41 individuals we’ve seen between June and August left seriously ill represent the devastating human cost of this trade. 

“We are working across the country to identify those responsible, seize illegal products, and bring cases to court. We use the full range of our enforcement powers and techniques to shut down these operations and bring offenders to justice.” 

This crackdown is part of the MHRA’s wider work to disrupt illegal botulinum toxin supply. Since May 2023, the Criminal Enforcement Unit, working closely with its partners in Border Force, has seized more than 4,700 vials of unlicensed botulinum toxin both at the border and inland.  

Almost all of the seized products originated in South Korea, including brands such as Botulax, reNTox, Innotox, and Toxpia, which are not authorised for sale in the UK. 

The Criminal Enforcement Unit also works with social media companies to remove illegal listings and disrupt criminal networks advertising unlicensed botulinum toxin. 

Understanding the health risks 

Botulism caused by botulinum toxin in cosmetic procedures is rare, but can be life-threatening. Symptoms can take up to four weeks to develop and may include difficulty swallowing, slurred speech and breathing difficulty. In severe cases, patients may require mechanical ventilation and intensive care treatment. 

Anyone who has recently received a botulinum toxin treatment and develops any of these symptoms should seek medical help immediately via NHS 111 or emergency services. 

Health Minister Stephen Kinnock said: “No one should have to suffer serious illness or risk their life because criminals are flooding the market with unsafe products.  

“This government is determined to crack down on cosmetic cowboys who exploit vulnerable consumers seeking cut-price treatments outside suitable medical settings. Through the MHRA’s criminal investigations and our new regulations, we’ll use the full force of the law against those who supply unlicensed medicines. 

“I would urge anyone considering a cosmetic procedure to consider the risks and find a reputable, insured, and qualified practitioner.”

MHRA Chief Safety Officer Dr Alison Cave said: ““Public safety is a top priority for the MHRA. Botulinum toxin is a prescription-only medicine and should only be sold or supplied in accordance with a prescription given by an appropriate prescriber such as a doctor or other qualified healthcare professional. 

“Buying botulinum toxin in any other circumstances significantly increases the risk of getting a product which is either falsified or not licensed for use in the UK. This means that there are no safeguards to ensure products meet the MHRA’s standards for quality and safety. As such, they can have life-threatening consequences for the people who take them. 

“If you are offered botulinum toxin without a medical consultation, in an informal setting, or at a price significantly below usual rates, this should be treated as a warning sign. Lower cost does not mean safe; it may put your health at risk and could lead to hospitalisation.” 

How to protect yourself and report concerns 

Licensed botulinum toxin products undergo rigorous testing and quality controls to ensure they contain the correct active ingredient at safe concentrations. Legitimate treatments should only be carried out by qualified healthcare professionals in proper clinical settings with appropriate emergency equipment available. 

Before any treatment, verify that your practitioner is medically qualified and registered with their professional body. Check that products being used are licensed in the UK by asking to see packaging and checking batch numbers. Be suspicious of unusually cheap prices, treatments offered in domestic settings, or practitioners who cannot provide proper credentials. 

The MHRA urges anyone who experiences side effects or complications after a cosmetic procedure to report them via the Yellow Card scheme at:

https://yellowcard.mhra.gov.uk/.